Last updated: April 23, 2026
Which companies supply dapagliflozin for commercial manufacture?
Dapagliflozin is manufactured and marketed under multiple branding and regulatory filings, with active supply anchored by the originator and major generics companies that received approvals through their own API/finished-dose supply chains. The commercial market is supported by:
- Originator/brand holder (market authorization and development): AstraZeneca (dapagliflozin; brand name Farxiga in many markets).
- Key global generics players (approved finished products and/or contract supply): suppliers include large-scale oral solid dose and API manufacturers that routinely support EU/US filings and tenders for SGLT2 inhibitors.
Which suppliers are tied to the dapagliflozin API and finished dose supply chain?
Commercial dapagliflozin supply typically splits into active pharmaceutical ingredient (API) and finished dosage form. In practice, the set of “suppliers” in procurement and tender contexts is the intersection of:
1) the marketing authorization holder / finished-dose manufacturer for each national dossier, and
2) the API supplier(s) named in the submission (where disclosed to regulators and dossier holders).
For dapagliflozin, the visible supplier landscape is dominated by AstraZeneca for the originator product and then expanded by generics manufacturers for approved equivalents.
What procurement-facing supplier types exist for dapagliflozin?
From a buyer perspective, suppliers usually fall into these categories:
- Finished-dose manufacturers providing tablets (API-to-finished transformation under GMP).
- API manufacturers supplying dapagliflozin or downstream intermediates (often under raw-material contracts to multiple finished-dose sites).
- Contract manufacturers that produce finished dose for brands and generics using supplied API or API procured by the CMOs.
What is the originator footprint for dapagliflozin?
- AstraZeneca is the originator and has the dominant role in defining product specifications, regulatory stewardship, and lifecycle management for dapagliflozin under its branded product programs (for example, Farxiga).
What do branded and generic filings imply about suppliers?
Where the originator holds the branded authorization, the manufacturing sites and API sources are defined in the regulatory dossier. When generics enter, the supplier base expands to:
- manufacturers that hold the approved generic dossiers in each country,
- sites that qualify for regulatory release testing, and
- API sources declared in the abbreviated or full dossiers, where required.
Who supplies dapagliflozin in the US and EU in practical terms?
In practical procurement terms:
- Brand procurement tracks AstraZeneca’s authorized finished-dose supply.
- Generic procurement tracks national marketing authorization holders and their authorized manufacturing sites for the tablet and declared API sources.
Regulatory reference points used to identify suppliers
For mapping suppliers, buyers and analysts typically anchor to:
- FDA labeling for manufacturing/distribution statements for finished doses (originator and approved generics).
- EMA product information (SmPC/EPAR) for marketed products and sometimes manufacturing site references.
- Regulatory submission dossiers (where accessible to dossier holders) to identify named API manufacturers and intermediate sources.
Key Takeaways
- AstraZeneca is the originator and the anchor for branded dapagliflozin supply (Farxiga across many markets).
- Market supply beyond the originator is carried by approved generic and contract manufacturing networks, with the supplier roster determined by each country’s marketing authorization and the manufacturing sites named in regulatory submissions.
- Supplier identification in procurement should be executed through finished-dose marketing authorization holders and their manufacturing sites, then cross-walked to API sources declared in regulatory dossiers for each approved product strength.
FAQs
-
Is AstraZeneca the only supplier of dapagliflozin?
No. AstraZeneca anchors branded supply, while multiple generic suppliers provide approved finished-dose products.
-
How do I identify the real “API supplier” for a dapagliflozin product?
Use the regulatory dossier or the marketing authorization for the specific product strength and then read the API source/manufacturing section.
-
Do API suppliers change for the same dapagliflozin generic?
They can, subject to regulatory change control and re-qualification for quality and bioequivalence expectations tied to the approved dossier.
-
Are suppliers the same across countries?
No. Manufacturing authorization holders and authorized sites vary by jurisdiction.
-
What is the fastest path to map dapagliflozin suppliers for procurement?
Map by approved finished-dose product per jurisdiction (then extract manufacturing sites), and map API sources from the same dossier.
References
[1] AstraZeneca. Farxiga (dapagliflozin) prescribing information (FDA label and product stewardship references).
[2] U.S. Food and Drug Administration (FDA). Drug Approval Package / FDA label references for dapagliflozin (Farxiga).
[3] European Medicines Agency (EMA). EPAR and product information for dapagliflozin-containing medicines (Farxiga and related authorized products).
